AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06727474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health-Related Quality of Life (HRQoL) with EQ-5D-3L
Description: The EQ-5D-3L and EQ-VAS questionnaires, administered at all visits, evaluated five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Responses generated a Health Status sequence and calculated the EQ-5D-3L Index. A visual analogue scale (VAS) rated health from 0 (worst) to 100 (best). Functional capacity was assessed using the Katz Index (IK) and Timed Up and Go (TUG), which measured the time to rise from a chair, walk 3 meters, and return. Anthropometric variables, measured by the same researcher (LP) at 1 month and 1 year, included limb circumferences using specific techniques. Muscle strength, evaluated with the EF-MRC scale, involved verbal commands for movement tests. Calf circumference was measured on the largest circumference area. Living conditions and work reintegration were recorded. Health issues detected during follow-up were referred to the clinic's coordinating physician for appropriate care.
Study NCT03345576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testosterone and LPWS
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
Study NCT03345576 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Testosterone and standard NMES
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral, multiple dose levels
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: Oral recommended phase 2 dose of MS-553
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Oral
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Oral
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV
Study NCT03492125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: IV
Study NCT03664115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes
Study NCT02371681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Different Drug combinations
Study NCT02371681 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: PET/CT Scans
Study NCT02371681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample Collection
Description: Sample Collection
Study NCT01204671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: One intramuscular injection
Study NCT01204671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: One intramuscular injection
Study NCT01204671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK2604409A
Description: One intramuscular injection
Study NCT04185038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study NCT01012817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02573714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
Study NCT02573714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Therapy
Description: Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Pain Therapy
Description: Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life - Sickle Cell Disease Module
Description: Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pediatric Quality of Life - Sickle Cell Disease Module
Description: Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faces Pain Scale - Revised
Description: All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
Study NCT02573714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faces Pain Scale - Revised
Description: All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
Study NCT01012817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01012817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01012817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01012817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03625544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumented posterolateral spinal fusion
Description: Instrumented posterolateral spinal fusion, with or without an additional interbody device
Study NCT03625544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral spinal fusion
Description: Instrumented posterolateral spinal fusion, with or without an additional interbody device
Study NCT03625544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs™ Granules
Description: 8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
Study NCT03625544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: 8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
Study NCT04393649 — intervention group
Intervention type: OTHER
Intervention: ESOGER
Description: Questionnaire
Study NCT03861026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NIRS (Masimo, O3TM Regional Oximetry)
Description: Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
Study NCT01035749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340274A
Description: One or two doses administered intramuscularly
Study NCT01035749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Influenza investigational vaccine GSK2340273A
Description: Two doses intramuscularly
Study NCT01035749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: One dose intramuscularly
Study NCT01535924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01535924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT04346953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video based exercise
Description: Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
Study NCT03035162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
Study NCT03035162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
Study NCT02783638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: 2 by 2
Study NCT02783638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 2 by 2
Study NCT01100502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Every 21 days by IV infusion (1.8 mg/kg)
Study NCT01100502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 21 days by IV infusion
Study NCT00948090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Description: Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
Study NCT01118052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01118052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Description: Given intraperitoneally
Study NCT00100906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-2
Description: Immunotherapy with interleukin-2
Study NCT00100906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA
Study NCT00057135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unit of use medication packaging
Study NCT00057135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mailed reminders to patient when medication refills are due
Study NCT00057135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Note to Mental Health Provider when refill is overdue
Study NCT00057135 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aligning all prescriptions to fall due on same date
Study NCT02001571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
Study NCT02358122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain rye
Description: A variety of cereal foods providing >100g/day wholegrain from rye
Study NCT02358122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat
Description: A variety of cereal foods providing >100g/day wholegrain from wheat
Study NCT02358122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat
Description: A variety of cereal foods providing 0g/day wholegrain
Study NCT04000178 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: polyurethane stent
Description: patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
Study NCT04000178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone stent
Description: silicone stent
Study NCT03521557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze and Postural Stability
Description: The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
Study NCT03521557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care Control
Description: The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
Study NCT03521557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
Study NCT01940965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study NCT01940965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biguanide
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01940965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZD
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01940965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-GI
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01940965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glinide
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT00073918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00073918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00073918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 tositumomab
Description: Given IV
Study NCT00073918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study NCT00073918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo ASCT given via central catheter
Study NCT04577105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simple chest tomography
Description: The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
Study NCT03654417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
Study NCT03654417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
Study NCT02980081 — intervention group
Intervention type: OTHER
Intervention: abdominal plain x-ray
Description: Abdominal plain x-ray as prescribed by the emergency physician
Study NCT01706562 — intervention group
Intervention type: DRUG
Intervention: Itraconazole
Description: Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
Study NCT00003039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study NCT01471977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education,counseling, default tracers,quality of care
Description: these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
Study NCT05418803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP1807 Tab. 2.5mg
Description: Rivaroxaban 2.5mg
Study NCT05418803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHP1807 Tab. 2.5mg
Description: Rivaroxaban 2.5mg
Study NCT05418803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1901 Tab. 2.5mg
Description: Rivaroxaban 2.5mg
Study NCT05418803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHR1901 Tab. 2.5mg
Description: Rivaroxaban 2.5mg
Study NCT01585883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Intervention
Description: Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
Study NCT01585883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management Intervention
Description: Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
Study NCT01407016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole IV 500 mg
Description: On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
Study NCT01324947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
Study NCT00763360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DisCoVisc®
Description: Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure